Researchers attack cancer with sustained siRNA delivery

There's a considerable amount of work being done in the lab to test the use of innovative nanoparticles to deliver siRNAs for a range of diseases.

At the University of Texas Health Sciences Centre in Houston a research team was presented with a problem: Using lipid nanoparticles to deliver a load of targeted chemotherapy drugs required a long course of twice-weekly injections to deliver the sustained dose necessary to treat cancer. So they developed nanoporous silicon particles to deliver siRNAs to mice which were engineered to develop ovarian cancer. The tumors in the mice shrank and toxicity levels were low or nonexistent.

"The multistage delivery system is revolutionary in that it allows the therapeutic payloads to cross the biological barriers in the body and reach their target," said team leader Mauro Ferrari, who is chairman of the Department of NanoMedicine and Biomedical Engineering at The University of Texas Medical School.

A second research team drawn from the University of Washington and Pacific Northwest National Laboratory, meanwhile, used nanoporous particles to deliver a sustained dose of CTLA-4 antibodies. The team felt they could use the particles to create a "reservoir" or antibodies that could provide a sustained release of the therapy over a long period of time. They reported that tumor suppression endured for a month with no signs of toxicity.

- here's the report from In-Pharmatechnologist
- and here's the report from Pharmaceutical Business Review

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.